[
    ") to reduce the cAMP content of CHO:huA1 cells. To initiate an experiment, growth medium is removed from the 12-well plates and cells are washed once with warm Hanks' buffered saline. The wash solution is then removed and replaced with fresh Hanks' solution containing forskolin (1 \u03bcM), rolipram (20 \u03bcM), N<sup>6</sup>-cyclopentyladenosine (CPA, 0.01 nM), adenosine deaminase (2 U/mL), and the test compound. Forskolin is used to stimulate the activity of adenylyl cyclase, rolipram to inhibit cAMP phosphodiesterase, adenosine deaminase to degrade endogenous adenosine, and CPA to cause a small increase of the number of activated adenosine receptors. After 6 min of incubation at 36\u00b0 C. in the presence of test compound, the incubation solution is removed and hydrochloric acid (final concentration 50 mm) is added to terminate drug action. The content of cAMP in acidified extracts of cells is determined by radioimmunoassay as previously described (Kollias-Baker et al., (1997), J. Pharmacol. Exp. Ther. 281: 761\u2013768). The effect of each test compound on cAMP content can be presented as a percentage of the value of cAMP content in the absence of drug (control, 100%).</p>EXAMPLE 3Binding Activity for Compounds of the Invention Against A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, A<sub>3 </sub>Adenosine ReceptorsTable 2, 3, and 4 give the receptor affinity profile of compounds structurally modified synthesized and described in this work. The values of affinity are determined by receptor binding assay at human A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B </sub>and A<sub>3 </sub>adenosine receptor subtypes cloned in CHO and HEK-293 cells using [<sup>3</sup>H]DPCPX, [<sup>3</sup>H]SCH 58261, [<sup>3</sup>H]DPCPX and [<sup>3</sup>H]MRE 3008F20 respectively. The biological results of the new series of compounds 5a\u20138 modified in 2 position is showed in Table 2.</p>TABLE 2Biological results of compounds 5a-8.<img id=\"EMI-C00027\" path=\"US07064204-20060620-C00027.TIF\" file=\"https://surechembl.org/api/assets/attachment/67519047/US/20060620/B2/000007/06/42/04/US07064204-20060620-C00027.TIF\"/> CompdXA<sub>1</sub>K<sub>i</sub>nMA<sub>2A</sub>K<sub>i</sub>nMA<sub>2B</sub>K<sub>i</sub>nMA<sub>3</sub>K<sub>i</sub>nMSCH\u20141212.3&gt;1000&gt;100058261<sup>a</sup>5a<sup>b</sup>4-OH&gt;1000&gt;1000&gt;1000-&gt;10005b<sup>b</sup>4-Cl&gt;1000&gt;1000&gt;1000&gt;10005c<sup>b</sup>2-OEt&gt;1000&gt;1000&gt;10003486<sup>b</sup>4-OCH<sub>2</sub>CO<sub>2</sub>Et&gt;1000&gt;1000&gt;1000&gt;10007<sup>b</sup>4-OCH<sub>2</sub>CO<sub>2</sub>H&gt;1000&gt;1000&gt;1000&gt;10008<sup>b</sup>OCH<sub>2</sub>CONHPh-4\u2032-1&gt;1000&gt;1000&gt;1000&gt;1000<sup>a</sup>Displacement of [<sup>3</sup>H]CHA binding (A<sub>1</sub>) at rat cortical membrane, displacement of [<sup>3</sup>H]CGS 21680 binding (A<sub>2A</sub>) at rat striatal membranes and displacement of [<sup>125</sup>I]AB MECA binding at human A<sub>3 </sub>adenosine receptors expressed in HEK-293 cells.<sup>b</sup>Displacement of [<sup>3</sup>H]DPCPX b",
    "ed in CHO cells and displacement of [<sup>3</sup>H]MRE 3008F20 binding at human A<sub>3 </sub>adenosine receptors expressed in CHO cells.</p>All the compounds synthesized were tested on all four adenosine receptor subtypes and the value of affinity are expressed in terms of SCH 58261 activity.</p>In general, we can note that the substitution of the furyl moiety with a substituted aromatic function causes a complete loss of affinity versus the A<sub>2A </sub>adenosine receptor subtype relative to the lead compound SCH 58261. This is supported by evidence that the furyl ring in the 2-position of the tricyclic structure is a necessary element to guarantee the activity of the molecule, probably because in this heterocycle is present an electronic condition favorable for interaction with the adenosine receptor.</p>Introduction of an ethoxy group in the ortho-position of the aromatic ring, in order to imitate the oxygen of the furan, was ineffective. The introduction of ester, acid or amide functions in the para position, in order to create an electronic condition for the formation of hydrogen bonds between the molecule and the adenosine receptor surface, was also ineffective.</p>Only the compound 5c show a poor affinity versus the A<sub>3 </sub>adenosine receptor subtype, but a complete selectivity.</p>The biological results of the compounds modified in 9 position are showed in Table 3.</p>TABLE 3A<sub>1</sub>A<sub>2A</sub>A<sub>2B</sub>A<sub>3</sub>CompRR<sup>1</sup>R<sup>2</sup>Ki nM<sup>a</sup>Ki nM<sup>b</sup>Ki nM<sup>c</sup>Ki nM<sup>d</sup>38CH<sub>3</sub>NHCH<sub>2</sub>CH<sub>3</sub>H50108122539CH<sub>3</sub>NH-Ph-p-OMeH260\u2014\u2014\u201440CH<sub>3</sub>N-Me-piperazineH3015635\u201441CH<sub>3</sub>SCH<sub>3</sub>H8.41.210.33542CH<sub>3</sub>S(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>H92.16922443Ph(CH<sub>2</sub>)<sub>3</sub>SCH<sub>3</sub>H1752231\u201444CH<sub>3</sub>NHCH<sub>2</sub>CH<sub>3</sub>CONHPh-p-OMe150\u221221371745CH<sub>3</sub>N-Me-piperazineCONHPh-p-OMe316\u201426\u201446CH<sub>3</sub>SCH<sub>3</sub>CONHPh-p-OMe703.12421247CH<sub>3</sub>SCH<sub>3</sub>COCHPh-p-OMe801545\u201448CH<sub>3</sub>SCH<sub>3</sub>COCH<sub>2</sub>Ph-p-isobutyl78050190\u201449CH<sub>3</sub>SCH<sub>3</sub>COCH<sub>2</sub>Ph-3,4-Medioxy704.13011050CH<sub>3</sub>NHCH<sub>2</sub>CH<sub>3</sub>COCH<sub>2</sub>Ph-3,4-Medioxy136616518352CH<sub>3</sub>NH-Ph-p-OHH666\u2014\u201430853CH<sub>3</sub>NHCH<sub>2</sub>CH<sub>3</sub>HClH4110362554CH<sub>3</sub>N-Me-piperazine 2HClH4813512\u201455CH<sub>3</sub>NHCH<sub>2</sub>CH<sub>3</sub>HClCONHPh-p-OMe10016239<sup>a</sup>Displacement of [<sup>3</sup>H]DPCPX binding at human A<sub>1 </sub>adenosine receptors expressed in CHO cells.<sup>b</sup>Displacement of [<sup>3</sup>H]SCH58261 binding at human A<sub>2A </sub>adenosine receptors expressed in CHO cells .<sup>c</sup>Displacement of [<sup>3</sup>H]DPCPX binding at human A<sub>2B </sub>adenosine receptors expressed in HEK-293 cells.<sup>d</sup>Displacement of [<sup>3</sup>H]MRE 3008F20 binding at human A<sub>3 </sub>adenosine receptors expressed in CHO cells.</p>As shown in the ta"
]